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Does predialysis nephrology care influence patient survival af-
ter initiation of dialysis?
Background. Early nephrology referral of patients with
chronic kidney disease (CKD) has been suggested to reduce
mortality after initiation of dialysis. This retrospective cohort
study of incident dialysis patients between 1995 and 1998 was
performed to address the association between frequency of
nephrology care during the 24 months before initiation of dial-
ysis and first-year mortality after initiation of dialysis.
Methods. Patient data were obtained from the Centers for
Medicare & Medicaid Services. Patients who started dialysis
between 1995 and 1998, and were Medicare-eligible for at least
24 months before initiation of dialysis, were included. One or
more nephrology visits during a month was considered a month
of nephrology care (MNC).
Results. Of the total 109,321 patients, only 50% had received
nephrology care during the 24 months before initiation of dial-
ysis. Overall, first-year mortality after initiation of dialysis was
36%. Cardiac disease was the major cause of mortality (46%).
After adjusting for comorbidity, higher mortality was associated
with increasing age (HR, 1.04 per year increase; 95% CI, 1.03 to
1.04) and more frequent visits to generalists (HR, 1.009 per visit
increase; 95% CI, 1.003 to 1.014) and specialists (HR, 1.012 per
visit increase; 95% CI, 1.011 to 1.013). Compared to patients
with ≥3 MNC in the six months before initiation of dialysis,
higher mortality was observed among those with no MNC dur-
ing the 24 months before initiation of dialysis (HR, 1.51; 95%
CI, 1.45 to 1.58), no MNC during the six months before initia-
tion of dialysis (HR, 1.28; 95% CI, 1.20 to 1.36), and one or two
MNC during the six months before initiation of dialysis (HR,
1.23; 95% CI, 1.18 to 1.29).
Conclusion. Nephrology care before dialysis is important,
and consistency of care in the immediate six months before
dialysis is a predictor of mortality. Consistent nephrology care
may be more important than previously thought, particularly
because the frequency and severity of CKD complications in-
crease as patients approach dialysis.
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Since its inception in 1972, the federally funded end-
stage renal disease (ESRD) program [1] has grown expo-
nentially, serving patients who have high morbidity and
mortality and require a considerable investment of health
care resources. Despite an increase in cost and improved
management of dialysis patients, morbidity and mortality
among ESRD patients remains high. The annual mortal-
ity rate for ESRD patients in the United States is approx-
imately 20% [2]. In 1999, white males who began dialysis
at the ages of 45 to 49, 55 to 59, and 65 to 69 years had ex-
pected remaining lifetimes of only 5.7, 4.3, and 3.1 years,
respectively [3]. Five-year survival of all patients start-
ing renal replacement therapy during 1982 to1987 was
only 40% in the United States, compared to 59% in Eu-
rope and 61% in Japan [4]. Although a higher level of co-
morbidity among ESRD patients [5] in the United States
could be a significant factor, it does not fully account for
the survival differences.
Until recently, the improvement of dialysis care was the
chief means of achieving better ESRD outcomes [6, 7].
However, with a better understanding of cardiovascular
risks [8] during earlier stages of chronic kidney disease
(CKD) and the emergence of therapeutic measures that
slow the progression of CKD and associated morbidities
[9–14], lack of nephrology care has been implicated as
a potential cause of poor ESRD outcomes. Despite the
potential benefits of early nephrology care [15], a signif-
icant fraction of patients with CKD are referred late to
the nephrologist [16–21].
Although some studies have found adverse clinical out-
comes to be associated with late nephrology referral, the
use of multiple definitions of “early” and “late” nephrol-
ogy referrals have left primary care providers unsure
about the timing and consistency of nephrology care re-
quired for their patients with CKD. We examined the
association between frequency of nephrology care dur-
ing 24 months before initiation of dialysis and first-year
mortality in a cohort of incident dialysis patients in the
United States.
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METHODS
Data on 1995 to 1998 incident ESRD patients were
obtained from the Centers for Medicare & Medicaid Ser-
vices (CMS). We included patients who were ≥67 years
old at initiation of dialysis and had Medicare as their pri-
mary payer with coverage for both Part A (institutional)
and Part B (physician/supplier) services 24 months be-
fore initiation of dialysis. The use of this age criterion
(≥67 years) ensured that data on all services, including
nephrology care, could be studied. The first service date
(FSD) for ESRD was used to identify the initiation of
dialysis.
Nephrology visits during the 24 months before initi-
ation of dialysis were identified from Medicare Part B
claims; nephrology visits were defined as any outpatient
visit to a nephrologist. Similarly, outpatient visits to gen-
eralists (internists and family practitioners) and special-
ists (all but generalists and nephrologists) were identified
during the six months before initiation of dialysis. Vis-
its that occurred in a hospital, emergency department,
or intensive care unit were excluded from analysis be-
cause these were regarded as being for acute care that was
not necessarily focused on management of the patient’s
chronic medical conditions. One or more nephrology vis-
its during a month was considered a month of nephrology
care (MNC). Nephrology visits that occurred within one
month before FSD were defined as study month –1; visits
that occurred during the 24th month before FSD were de-
fined as study month –24. Patients were divided into two
major groups: those who received nephrology care dur-
ing the 24 months before initiation of dialysis and those
who did not receive any care during the same period.
The patients who received care during the 24 months be-
fore initiation of dialysis were further divided into three
subgroups, based on the frequency of MNC during the
six months before initiation of dialysis: no MNC, 1 to 2
MNC, and ≥3 MNC.
Laboratory measures were obtained from the ESRD
Medical Evidence Report (Form CMS-2728), which in-
cluded data recorded within 45 days of initiation of
dialysis.
Because anemia is a common complication of advanc-
ing CKD and is treated with recombinant human erythro-
poietin (rHuEPO), we categorized patients into three
groups based on rHuEPO use during the 24 months be-
fore initiation of dialysis: no rHuEPO use, inconsistent
rHuEPO use, and consistent rHuEPO use. This catego-
rization was derived from claims data, and was based on
the frequency with which patients receive rHuEPO, and
may or may not be related to their visits to physicians’ of-
fice. Patients with no rHuEPO were defined as those who
did not receive any rHuEPO during the 24 months before
initiation of dialysis. Patients with inconsistent rHuEPO
were defined as those who initiated rHuEPO treatment
≥3 months before the FSD and received rHuEPO for
fewer than half of the months from the first month of
rHuEPO treatment to the FSD, or those whose rHuEPO
was initiated within three months before the FSD, and
who received rHuEPO in ≤2 of the three months before
initiation of dialysis. Patients with consistent rHuEPO
were defined as those who initiated rHuEPO ≥3 months
before FSD and received rHuEPO treatment for more
than half of the months from the month of first rHuEPO
treatment to the FSD, or those whose rHuEPO was initi-
ated within three months before FSD and who received
rHuEPO in all three months. Number of months on
rHuEPO treatment was defined as the cumulative num-
ber of months in which a patient received rHuEPO treat-
ment, regardless of the number of administrations [22].
Comorbidity index was calculated using the method
of Charlson et al [23], which was later adapted by Deyo
et al [24] for application with claims data. This score was
a single number derived for each patient included in the
analysis, and was a measure of the overall comorbidity
burden in the patient. The 24 months before initiation
of dialysis were used as the comorbidity characterization
period; Medicare Part A inpatient claims were used to de-
termine the patient’s total Charlson score for this period.
All International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM) diagnosis fields
were searched for codes previously described [24], in-
cluding codes for diabetes, hypertension, congestive heart
failure, ischemic heart disease, myocardial infarction, car-
diac dysrhythmia, cardiac arrest, pericarditis, peripheral
vascular disease, cerebrovascular accident/transient is-
chemic attack, chronic obstructive pulmonary disease,
and cancer. The total score for an individual was calcu-
lated as the sum of the weights accumulated during the
two-year period. The resulting scores were grouped into
the categories: 0, 1, 2, 3, 4, and ≥5 (0 = least comorbidity;
5 = most comorbidity). This comorbidity index has pre-
viously been applied to dialysis populations and found to
be strongly associated with mortality and costs [25].
We used Cox proportional hazard analysis to estimate
risk of death. Two models were developed. The first
model included age, gender, race, serum albumin, and
creatinine values at initiation of dialysis, and the presence
of diabetes, status of rHuEPO use, and MNC before ini-
tiation of dialysis. The second model was based on the
variables used in the first model, and was adjusted for
comorbidity level using Charlson scores. Survival curves
comparing patients with <3 MNC and patients with ≥3
MNC during the six months before initiation of dialy-
sis were developed and adjusted by the corrected group
prognosis method for Charlson score [26]. To satisfy the
proportional hazards assumption, the effect of diabetes
on mortality was verified, and was found to be pro-
portional. Additionally, diabetes was included as a stra-
tum in multivariate Cox regression analysis adjusted for
comorbidity.
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Table 1. Characteristics of patients ≥67 years old who initiated dialysis between 1995 and 1998 in the United States
Did not receive nephrology Did receive nephrology care in the 24 months
care in the 24 months before initiation of dialysis
before initiation of dialysis MNC in the 6 months before initiation of dialysis
0 1 to 2 ≥3Characteristic
Patients number 55,087 5820 24,943 23,471
Age years, mean 75.5 74.9 75.2 74.7
Female % 50 5 24 21
Race %
White 73.1 69.7 74.0 74.7
Black 22.8 26.4 22.3 21.1
Asian 2.9 2.9 2.7 3.4
Native American 1.3 1.0 1.0 0.8
Cause of CKD %
Diabetes 36.3 42.8 40.7 39.9
Hypertension 35.2 36.3 35.9 34.3
Glomerulonephritis 6.0 6.5 7.3 10.6
Other 22.6 14.4 16.1 15.3
Charlson score %
Charlson 0 37.9 29.0 30.1 35.7
Charlson 1 11.8 11.4 12.1 12.6
Charlson 2 12.9 12.7 14.2 12.9
Charlson 3 11.6 12.6 13.2 12.4
Charlson 4 8.8 10.8 10.6 9.78
Charlson 5 17.1 23.5 19.7 16.9
Laboratory values
Serum creatinine mg/dL 7.2 7.3 6.9 7.1
GFR mL/min/1.73m2 8.4 8.2 8.4 8.1
Serum albumin g/dL 3.1 3.2 3.3 3.4
Hematocrit % 28.6 28.5 28.8 29.5
Non-nephrology visits (mean ± SD visits during the 6 months prior to initiation of dialysis)
Generalist 0.57 ± 1.96 0.65 ± 2.33 0.58 ± 1.99 0.44 ± 1.80
Specialist 11.9 ± 10.6 11.8 ± 10.6 13.2 ± 10.1 11.2 ± 8.6
Abbreviations are: GFR, glomerular filtration rate; MNC, months of nephrology care; CKD, chronic kidney disease.
The ESRD Death Notification form (Form CMS-2746)
was used to ascertain the time and cause of death. This
form is filled out by the dialysis facility upon the death
of a dialysis patient. Survival time was calculated using
the FSD and ESRD Death Notification form. Causes of
death were grouped into these categories: cardiac, infec-
tion, vascular, malignancy, and other/unknown.
RESULTS
A total of 136,090 patients initiated dialysis between
January 1, 1995 and December 31, 1998. Of these, 26,769
were excluded because of the absence of Medicare Part
A claims, or because Medicare was not the primary
payer during the 24 months before initiation of dialysis
(these circumstances would limit the ability to determine
nephrology care, as well as other forms of care before ini-
tiation of dialysis). Thus, 109,321 patients (80.3% of the
elderly ESRD population) constituted the final study co-
hort. The numbers of incident dialysis patients ≥67 years
old in 1995, 1996, 1997, and 1998 were 24,744, 26,113,
29,211, and 29,253, respectively. The distributions of age,
gender, and race among the excluded patients were
similar to those in the final study cohort.
The mean ± SD age was 75 ± 5.8 years, 51% were male,
73% were white, and 22% were black. The cause of CKD
was diabetes in 38%, hypertension in 35%, glomeru-
lonephritis in 7%, and various other causes in 19% of
patients. Hypertension was present in 82%, congestive
heart failure in 65%, ischemic heart disease in 59%, dia-
betes in 53%, and peripheral vascular disease in 41% of
patients. Table 1 provides demographic, clinical, and lab-
oratory characteristics of study patients according to fre-
quency of nephrology visits. Compared to patients with
no MNC, patients with any MNC were more likely to be
younger, male, white, and diabetic, and to have higher
serum albumin and hematocrit levels and more comor-
bidity at initiation of dialysis. Patients with ≥3 MNC had
less frequent visits to generalists compared to patients
with <3 MNC.
Nephrology care
A total of 55,087 patients (50%) had no MNC during
the 24 months before initiation of dialysis. Among those
who had nephrology care during the 24 months before
initiation of dialysis, 37% had their first nephrology visit
during the six months before initiation of dialysis. Be-
tween 1995 and 1998, the proportion of patients who had
a nephrology visit within 24 months before initiation of
dialysis increased from 48% to 51%. In addition, between
1995 and 1998, the proportion of patients who had ≥3
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Table 2. Distribution of months of nephrology care (MNC) among incident dialysis patients between 1995 and 1998
1995 1996 1997 1998
No nephrology care in the 24 months before initiation of dialysis 52% 51% 50% 49%
MNCa in the 6 months before initiation of dialysis
0 5% 5% 6% 5%
1–2 23% 23% 23% 23%
≥3 20% 21% 21% 23%
ESRD, end-stage renal disease.
aMNC, in the 6 months before initiation of dialysis.
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Fig. 1. Increase in mean months of nephrology care (MNC) as patients
approached dialysis.
MNC during the six months before initiation of dialysis
also increased from 20% to 23% (Table 2).
The mean number of MNC increased as patients ap-
proached dialysis (Fig. 1). In addition, with the pro-
gression of CKD the percentage of patients with a
higher number of MNC also increased between −24 and
−1 months (Fig. 2).
Mortality
Overall, first-year mortality after initiation of dialy-
sis was 36%. Patients who did not receive nephrology
care in the 24 months before initiation of dialysis had
51% mortality, while patients with no MNC, 1 to 2 MNC,
and ≥3 MNC during the six months before initiation of
dialysis had 35%, 33%, and 25% mortality, respectively.
The major causes of mortality were cardiac (46%), infec-
tion (13%), vascular (7%), malignancy (5%), and other
(29%). A Cox survival curve adjusted for comorbidity
showed higher mortality among patients with <3 MNC
compared to patients with ≥3 MNC during the six months
before initiation of dialysis (Fig. 3).
Risk factors of first year mortality
Unadjusted for comorbidity. A multivariate Cox re-
gression analysis revealed a higher risk of first-year mor-
tality after initiation of dialysis in patients with increasing
age (HR, 1.04 per year increase; 95% CI, 1.03 to 1.04),
more frequent visits to generalists (HR, 1.01 per visit
increase; 95% CI, 1.006 to 1.017) and specialists (HR,
1.017 per visit increase; 95% CI, 1.016 to 1.018), and no
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Fig. 2. Increase in cumulative months of nephrology care (MNC) as
patients approached dialysis. Each curve represents number of MNC
(range: 1 to 8).
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Fig. 3. Cox survival curves by number of months of nephrology care
(MNC), adjusted for comorbidity.
nephrology visits during the 24 months before initiation
of dialysis (HR, 1.50; 95% CI, 1.44 to 1.56), no visits dur-
ing the six months before initiation of dialysis (HR, 1.33;
95% CI, 1.25 to 1.41), and one or two visits during the six
months before initiation of dialysis (HR, 1.23; 95% CI,
1.19 to 1.29) compared to patients with ≥3 visits during
that period. There was a lower risk of death among blacks
(HR, 0.80; 95% CI, 0.78 to 0.83), Native Americans (HR,
0.72; 95% CI, 0.64 to 0.81), and Asians (HR, 0.73; 95%
CI, 0.67 to 0.78) compared to whites; females (HR, 0.90;
95% CI, 0.88 to 0.92) compared to males; patients with
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Table 3. Factors associated with first-year mortality among patients ≥67 years old who initiated dialysis between 1995 and 1998 in the United
States: Multivariate analysis unadjusted for comorbidity
Covariates at initiation of dialysis Hazard ratio 95% CI P value
Age (per year increase) 1.04 1.03, 1.04 <0.0001
Female (reference: male) 0.90 0.88, 0.92 <0.0001
Race (reference: white)
Black 0.83 0.81, 0.86 <0.0001
Native American 0.78 0.69, 0.88 <0.0001
Asian 0.75 0.71, 0.81 <0.0001
rHuEPO use before initiation of dialysis (reference: no use)
Inconsistent 0.87 0.83, 0.91 0.0008
Consistent 0.74 0.71, 0.78 <0.0001
Laboratory values
Serum albumin (per g/dL increase) 0.76 0.75, 0.78 <0.0001
Serum creatinine (per mg/dL increase) 0.953 0.97, 0.957 <0.0001
MNC before initiation of dialysis (reference: ≥3 MNC in the 6 months before initiation of dialysis)
No MNC during the 24 months before initiation of dialysis 1.48 1.44, 1.55 <0.0001
No MNC during the 6 months before initiation of dialysis 1.30 1.22, 1.38 <0.0001
1 to 2 MNC during the 6 months before initiation of dialysis 1.19 1.14, 1.24 <0.0001
Non-nephrology visits (per each visit increase during the 6 months prior to initiation of dialysis)
Generalist 1.012 1.006, 1.017 <0.0001
Specialist 1.017 1.016, 1.018 <0.0001
MNC; months of nephrology care; rHuEPO, recombinant human erythropoietin.
higher serum albumin (HR, 0.75 per g/dL increase; 95%
CI, 0.74 to 0.76) and creatinine (HR, 0.94 per mg/dL in-
crease; 95% CI, 0.93 to 0.95) levels; and patients with
inconsistent (HR, 0.93; 95% CI, 0.88 to 0.97) or consis-
tent (HR, 0.85; 95% CI, 0.81 to 0.90) use of rHuEPO
compared to those with no use of rHuEPO (Table 3).
Adjusted for comorbidity and non-nephrology visits.
After adjusting for comorbidity, higher mortality was as-
sociated with increasing age (HR, 1.04 per year increase;
95% CI, 1.03 to 1.04), more frequent visits to generalists
(HR, 1.009 per visit increase; 95% CI, 1.003 to 1.014) and
specialists (HR, 1.012 per visit increase; 95% CI, 1.011 to
1.013), and no MNC during the 24 months before initia-
tion of dialysis (HR, 1.51; 95% CI, 1.45 to 1.58), no MNC
during the six months before initiation of dialysis (HR,
1.28; 95% CI, 1.20 to 1.36), and one or two MNC during
the six months before dialysis (HR, 1.22; 95% CI, 1.18
to 1.29) compared to patients with ≥3 MNC during that
period.
The risk of death was lower among blacks (HR, 0.81;
95% CI, 0.78 to 0.83), Native Americans (HR, 0.74; 95%
CI, 0.66 to 0.83), and Asians (HR, 0.80; 95% CI, 0.74 to
0.86) compared to whites; females (HR, 0.91; 95% CI,
0.89 to 0.93) compared to males; patients with higher
serum albumin (HR, 0.76 per g/dL increase; 95% CI, 0.74
to 0.77) and creatinine (HR, 0.95 per mg/dL increase;
95% CI, 0.94 to 0.96) levels; and patients with inconsis-
tent (HR, 0.88; 95% CI, 0.84 to 0.92) or consistent (HR,
0.83; 95% CI, 0.79 to 0.88) use of rHuEPO compared
to those with no use of rHuEPO. The risk of death was
also progressively higher among patients with Charlson
scores of 1 (HR, 1.11; 95% CI, 1.06 to 1.15), 2 (HR, 1.34;
95% CI, 1.29 to 1.39), 3 (HR, 1.41; 95% CI, 1.36 to 1.47),
4 (HR, 1.50; 95% CI, 1.44 to 1.56), and 5 (HR, 1.77; 95%
CI, 1.71 to 1.83) compared to patients with a Charlson
score of zero (Table 4).
DISCUSSION
Although overall mortality among dialysis patients de-
creased by 12.7% between 1989 and 1998, it remains high
[3]. In a sample of 109,321 incident dialysis patients ≥67
years old, we observed a high mortality (36%) during
the first year after initiation of dialysis. Patients who had
≥3 MNC during the six months before initiation of dial-
ysis had lower first-year mortality (25%) than patients
who had <3 MNC (41%). A multivariate analysis ad-
justing for comorbid conditions revealed that older age,
a greater number of comorbid conditions, and a lack of
rHuEPO use before initiation of dialysis were associated
with higher mortality, while higher serum albumin and
creatinine values at initiation of dialysis and a greater
number of MNC during the six months before initiation
of dialysis were associated with lower first-year mortality
after initiation of dialysis. A minimal increase in first-year
mortality was also observed with more frequent visits to
generalists and specialists. The addition of comorbidity
in our multivariate analysis did not change the advan-
tageous association of MNC before initiation of dialy-
sis with improved first-year survival after initiation of
dialysis.
Patterns of nephrology referral during CKD have been
associated with conflicting post-ESRD mortality out-
comes [15, 18, 27–29]. These conflicting outcomes could
be the result of inconsistencies in the definitions used for
early versus late nephrology referral. In previous stud-
ies, late referral has been defined as a patient being seen
by a nephrologist less than one month [27], four months
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Table 4. Factors associated with first-year mortality among patients ≥67 years old who initiated dialysis between 1995 and 1998 in the United
States: Multivariate regression analysis adjusted for comorbidity
Covariates at initiation of dialysis Hazard ratio 95% CI P value
Age (per year increase) 1.04 1.03, 1.04 <0.0001
Female (reference: male) 0.91 0.89, 0.93 <0.0001
Race (reference: white)
Black 0.83 0.80, 0.85 <0.0001
Native American 0.78 0.69, 0.88 <0.0001
Asian 0.80 0.74, 0.86 <0.0001
Comorbidity (reference: Charlson 0)
Charlson 1 1.06 1.01, 1.10 0.005
Charlson 2 1.25 1.20, 1.30 <0.0001
Charlson 3 1.30 1.25, 1.36 <0.0001
Charlson 4 1.37 1.31, 1.43 <0.0001
Charlson 5 1.56 1.51, 1.62 <0.0001
rHuEPO use before initiation of dialysis (reference: no use)
Inconsistent 0.86 0.82, 0.92 <0.0001
Consistent 0.76 0.72, 0.80 <0.0001
Laboratory values
Serum albumin (per g/dL increase) 0.76 0.75, 0.78 <0.0001
Serum creatinine (per mg/dL increase) 0.96 0.95, 0.96 <0.0001
MNC before initiation of dialysis (reference: ≥3 MNC in the 6 months before initiation of dialysis)
No MNC during the 24 months before initiation of dialysis 1.50 1.44, 1.56 <0.0001
No MNC during the 6 months before initiation of dialysis 1.27 1.20, 1.35 <0.0001
1 to 2 MNC during the 6 months before initiation of dialysis 1.18 1.14, 1.24 <0.0001
Non-nephrology visits (per each visit increase during the 6 months prior to initiation of dialysis)
Generalist 1.009 1.003,1.014 0.001
Specialist 1.012 1.011,1.013 <0.0001
MNC; months of nephrology care; rHuEPO, recombinant human erythropoietin.
[20, 29], or six months [15] before initiation of dialysis.
Variations in definitions lead to variations in the calcu-
lated amount and time of delivered nephrology care. In
contrast, our study defined the nephrology care accord-
ing to the frequency of encounters with nephrologists, a
measure that is more representative of exposure to ser-
vices provided by nephrologists and consistency of care.
Our finding of an independent association of frequent
nephrology care with improved survival after initiation
of dialysis is consistent with the finding of a study [21]
of dialysis patients enrolled in the New Jersey Medicaid
and Medicare programs who had been diagnosed with
CKD more than 12 months before initiation of dialysis.
Patients who saw a nephrologist on fewer than five occa-
sions in the year before initiation of dialysis had a 15%
higher mortality rate in the first year of dialysis than those
who had five or more nephrologist visits during the same
period. Such a relationship could be the result of coordi-
nated care among generalists and specialists, an essential
aspect of optimal clinical care.
Surprisingly, 50% of our study cohort was not seen by a
nephrologist at all during the 24 months before initiation
of dialysis. Among those seen by a nephrologist, 37% had
their first nephrology visit only during the six months be-
fore initiation of dialysis. Overall lack of nephrology care
among CKD patients insured by Medicare, and frequent
visits to generalists and other specialists among patients
who received less consistent nephrology care, may rep-
resent unawareness of the diagnosis of CKD or benefits
of earlier nephrology care among primary care providers
rather than inadequate access to health care services.
Several recommendations and guidelines for appro-
priate timing of nephrology referral for CKD were in
place during our study period (1995–1998). In the United
States, the National Institutes of Health Consensus Con-
ference of 1993 recommended referral of patients with
CKD for nephrology service if the serum creatinine level
rose above 1.5 mg/dL in women and 2.0 mg/dL in men
[30]. The United Kingdom Renal Association recom-
mends that all patients with serum creatinine value of
>150 lmol/L (1.7 mg/dL) be referred for renal assessment
[31], while the Canadian Society of Nephrology recom-
mends one year for adequate preparation of a patient for
dialysis [32]. However, the inadequate dissemination of
these guidelines to the health care provider community
may prevent them from being widely followed.
In our study population, increased exposure to
nephrology care during the six months before initiation of
dialysis was significantly associated with improved first-
year survival. The six-month period before initiation of
dialysis is probably the crucial time for preparation for
long-term dialysis, including psychosocial adjustment to
a new lifestyle, placement of a vascular access [33], and
treatment of anemia [34] and malnutrition [35]. How-
ever, prevention of cardiovascular disease would require
much longer period of care, as several years of consistent
nephrology care before initiation of dialysis has shown to
be associated with a better long-term survival [15].
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We found a strong an independent association between
consistency of rHuEPO use before initiation of dialysis
and first-year mortality after initiation of dialysis. Al-
though the use of rHuEPO can lead to a dramatic im-
provement in hematocrit levels, anemia among predial-
ysis and dialysis patients remains common [36–38], and
current standards of care are not being met [39]. The as-
sociation of anemia with mortality has been established
in a large epidemiologic study [38]. Anemia is an inde-
pendent risk factor for the development of cardiovascular
disease in dialysis patients [40–42] and in CKD patients
before dialysis [43, 44]. More important, correction of
anemia with rHuEPO is associated with improvement
in left ventricular hypertrophy and reduced frequency
of cardiac complications [45, 46]. However, the use of
rHuEPO before initiation of dialysis may be a marker of
better clinical care, and its independent association with
improved survival in our study may reflect other aspects
of care, in addition to correction of anemia.
Our study also confirmed the previously established
associations of lower serum albumin [47, 48] and cre-
atinine [47] levels with poor survival. However, these
commonly measured variables not only serve as nutri-
tional markers, but are also representative of the severity
of coexisting diseases [49]. Consequently, although low
serum albumin and creatinine levels may identify pa-
tients at greater risk of death, it remains to be proven
whether closer surveillance and interventions targeted at
improving serum albumin levels would lead to decreased
mortality.
Late nephrology referral is a universal problem, and
its association with poor clinical outcomes has long been
debated [16, 21, 50]. However, the established renopro-
tective interventions, such as strict blood pressure con-
trol [51, 52] and use of angiotensin-converting enzyme
inhibitors [11, 53, 54] or angiotensin receptor blockers,
necessitate detection and appropriate interventions at
an early stage of CKD. Treatment of dyslipidemia [55]
with lipid-lowering agents [56] is not only beneficial in
this population for reducing risk of cardiovascular dis-
ease [57], but they could also play a role in retarding the
progression of CKD [14]. In addition, during later stages
of CKD, complications such as malnutrition [58] and ane-
mia, respectively, require timely dietary intervention [59]
and treatment with rHuEPO.
The results of our study must be interpreted with its
limitations in mind. The retrospective nature of the study
allows it to describe the relationship between factors as-
sociated with first-year mortality but not to establish or
imply causality. The inclusion criteria limiting entry to pa-
tients aged ≥67 years limits the generalizability of the re-
sults. However, previous studies [20, 21] have confirmed
similar association in younger dialysis patients. As the
overall average age of patients initiating dialysis is in-
creasing, our results can be generalized, at least to the
elderly Medicare population. Although the results of our
study showed an increase in mortality with more frequent
visits to generalists and other specialists, the impact was
minimal. The issue of health care quantity or quality and
its impact on long-term survival is a complex one. A bet-
ter survival with increase exposure to nephrology care ob-
served in our study may be a marker of overall better and
a close coordination between generalists and nephrolo-
gists. To establish an association of nephrology care in-
dependent of generalist or other specialist care with im-
proved patient survival would require a quantification of
care provided by all health care providers. Future studies
are required to establish such a relationship.
CONCLUSION
Higher mortality in the first year after initiation of dial-
ysis among patients aged ≥67 years was independently as-
sociated with less frequent nephrology care. In addition,
higher mortality was associated with older age, male gen-
der, white race, higher comorbidity, lower albumin and
hematocrit values, lack of rHuEPO use, and frequent vis-
its to generalists and specialists. The results of this study
and other recent studies [20, 21, 60] indicate a need for
urgent attention to the provision of optimal nephrology
care during advance stages of CKD in order to reduce
high mortality among these patients [56, 58, 59, 61].
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